Bridge Biotherapeutics Announces China NMPA Clearance of IND for BBT-401, a Pellino-1 Inhibitor for UC

• China NMPA cleared the IND application of BBT-401 submitted on September 25, 2019
• The Phase I clinical study in China will be initiated in May 2020

SEONGNAM, South Korea, Dec. 26, 2019 /PRNewswire/ -- Bridge Biotherapeutics Inc. (KOSDAQ: 288330), a clinical stage biotech company headquartered in Seongnam, Republic of Korea announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) cleared the Investigational New Drug (IND) application submitted as of September 25, 2019 for BBT-401, a potent first-in-class Pellino-1 inhibitor for the treatment of ulcerative colitis (UC).

Bridge Biotherapeutics plans to initiate a Phase I study of BBT-401 in Chinese subjects in May 2020. The safety, tolerability and pharmacokinetic data of the drug candidate will be assessed with single and multiple ascending oral doses in the study. The study will include 30 healthy volunteers and is targeting to complete by end of 2020.

The company entered a partnership with Daewoong Pharmaceutical to jointly develop BBT-401, under the license and co-development agreement signed in December 2018. Daewoong Pharmaceutical acquired the exclusive right for the development and commercialization of BBT-401 in 22 Asian countries, including China, Japan and Korea. The two companies have been closely collaborating on the clinical development for BBT-401 in Asian countries, preceded by the Phase II study in the U.S. with active UC patients.

"We believe the IND clearance of BBT-401 will move our team forward in bringing the innovative treatment option to patients with ulcerative colitis," and "We will keep focused on developing the drug to address huge unmet medical needs in UC," stated James Lee, CEO of Bridge Biotherapeutics.

"Daewoong Pharmaceutical is proud of the IND clearance of BBT-401 in China. Daewoong will also make the best effort to develop the First-in-Class therapeutics starting with the Phase I study in China," Sengho Jeon, CEO of Daewoong Pharmaceutical said.

BBT-401, discovered by SKKU (Sungkyunkwan University) and KRICT (Korea Research Institute of Chemical Technology) is a GI-tract restricted small molecule inhibitor of Pellino-1. From the Phase I study, the drug candidate was proved to be well tolerated and safe in humans with local distribution in colon. The drug candidate in now on its Phase II study in selected groups of active patients with UC in the U.S.

About Bridge Biotherapeutics

Bridge Biotherapeutics Inc.(KOSDAQ: 288330), based in South Korea, US and China is a clinical stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics, focusing on therapeutic areas with high-unmet needs, such as ulcerative colitis, fibrotic diseases, and cancers. BBT-401, the first-in-class Pellino-1 inhibitor for treatment of ulcerative colitis, is currently in Phase II in the US, and BBT-877, an autotaxin inhibitor to treat various fibrosing interstitial lung diseases including idiopathic pulmonary fibrosis (IPF), was licensed to Boehringer-Ingelheim for further development in July 2019 with potential license value more than 1.1 billion euro. BBT-176, a potent targeted cancer therapy for non–small cell lung cancer (NSCLC) is also in development. Bridge Biotherapeutics is a resident company of JLABS @ Shanghai.

SOURCE Bridge Biotherapeutics, Inc.